机构:[1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria[2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China血液科首都医科大学宣武医院[3]Clinical Pathology, Paracelsus Private Medical University of Salzburg, Salzburg, Austria[4]Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
Effective systemic therapy for advanced pseudomyxoma peritonei (PMP) is the focus of investigation. We describe a case of PMP arising from an adenoma of the appendix in a 58-year-old man. First, the patient underwent explorative laparotomy with ileocoecal resection, but without possibility of major tumor debulking due to adhesive gross tumor masses. Subsequently, six cycles of Folfox IV chemotherapy were administered, without response, but with severe side effects. Upon progressive disease, a combination of bevacizumab and capecitabine led to a long term stabilization of disease and obvious improvement of performance status. Our case suggests that modulation of tumor microenvironment and angiogenesis by bevacizumab, potentially augmented by monochemotherapy, may be beneficial in borderline tumors such as PMP.
第一作者机构:[1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria[2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构:[*]Landeskrankenhaus Natters, Abteilung fur Innere Medizin, In der Stille 20, Natters 6161 Austria
推荐引用方式(GB/T 7714):
Wan-Ling Sun ,Georg Hutarew ,Johann Gradl ,et al.Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine[J].CANCER BIOLOGY & THERAPY.2009,8(15):1459-1462.doi:10.4161/cbt.8.15.8943.
APA:
Wan-Ling Sun,,Georg Hutarew,,Johann Gradl,,Melanie Gratzl,,Hubert Denz&Michael Fiegl.(2009).Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.CANCER BIOLOGY & THERAPY,8,(15)
MLA:
Wan-Ling Sun,,et al."Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine".CANCER BIOLOGY & THERAPY 8..15(2009):1459-1462